Short term neuromuscular blockers good in ARDS

In this trial of 340 ICU patients with ARDS, they were randomized to 48 hours of cisatracurium or placebo. The adjusted in-hospital mortality was lower in the cisatracurium group (hazard ratio 0.68, CI 0.48-0.98). Cisatracurium short term use should be considered in patients with ARDS (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment